These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34262782)

  • 1. Developing a digital health strategy for people who use drugs: Lessons from COVID-19.
    Perri M; Guta A; Gagnon M; Bonn M; Leece P; Bayoumi AM; Rai N; Touesnard N; Strike C
    Digit Health; 2021; 7():20552076211028404. PubMed ID: 34262782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "We have to be uncomfortable and creative": Reflections on the impacts of the COVID-19 pandemic on overdose prevention, harm reduction & homelessness advocacy in Philadelphia.
    Aronowitz SV; Engel-Rebitzer E; Lowenstein M; Meisel Z; Anderson E; South E
    SSM Qual Res Health; 2021 Dec; 1():100013. PubMed ID: 34870265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 and People Who Use Drugs - A Commentary.
    Walters SM; Seal DW; Stopka TJ; Murphy ME; Jenkins WD
    Health Behav Policy Rev; 2020 Oct; 7(5):489-497. PubMed ID: 33134405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study.
    Russell C; Ali F; Nafeh F; Rehm J; LeBlanc S; Elton-Marshall T
    J Subst Abuse Treat; 2021 Oct; 129():108374. PubMed ID: 34080545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rapid ethnographic study of risk negotiation during the COVID-19 pandemic among unstably housed people who use drugs in Rhode Island.
    Collins AB; Edwards S; McNeil R; Goldman J; Hallowell BD; Scagos RP; Marshall BDL
    Int J Drug Policy; 2022 May; 103():103626. PubMed ID: 35228056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responding to a surge in overdose deaths: perspectives from US syringe services programs.
    Frost MC; Austin EJ; Corcorran MA; Briggs ES; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Des Jarlais DC; Williams EC; Glick SN
    Harm Reduct J; 2022 Jul; 19(1):79. PubMed ID: 35854351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative examination of substance use service needs among people who use drugs (PWUD) with treatment and service experience in Ontario, Canada.
    Russell C; Ali F; Nafeh F; LeBlanc S; Imtiaz S; Elton-Marshall T; Rehm J
    BMC Public Health; 2021 Nov; 21(1):2021. PubMed ID: 34742267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of COVID-19 on access to harm reduction, substance use treatment and recovery services in Scotland: a qualitative study.
    Schofield J; Dumbrell J; Matheson C; Parkes T; Bancroft A
    BMC Public Health; 2022 Mar; 22(1):500. PubMed ID: 35287630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone.
    Perri M; Kaminski N; Bonn M; Kolla G; Guta A; Bayoumi AM; Challacombe L; Gagnon M; Touesnard N; McDougall P; Strike C
    Harm Reduct J; 2021 Aug; 18(1):85. PubMed ID: 34353323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harm reduction via online platforms for people who use drugs in Russia: a qualitative analysis of web outreach work.
    Davitadze A; Meylakhs P; Lakhov A; King EJ
    Harm Reduct J; 2020 Dec; 17(1):98. PubMed ID: 33298081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remote harm reduction services are key solutions to reduce the impact of COVID-19-like crises on people who use drugs: evidence from two independent structures in France and in the USA.
    Torres-Leguizamon M; Favaro J; Coello D; Reynaud EG; Néfau T; Duplessy C
    Harm Reduct J; 2023 Jan; 20(1):1. PubMed ID: 36611167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intersecting substance use treatment and harm reduction services: exploring the characteristics and service needs of a community-based sample of people who use drugs.
    Krawczyk N; Allen ST; Schneider KE; Solomon K; Shah H; Morris M; Harris SJ; Sherman SG; Saloner B
    Harm Reduct J; 2022 Aug; 19(1):95. PubMed ID: 36002850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethical by Design: Engaging the Community to Co-design a Digital Health Ecosystem to Improve Overdose Prevention Efforts Among Highly Vulnerable People Who Use Drugs.
    Claborn KR; Creech S; Whittfield Q; Parra-Cardona R; Daugherty A; Benzer J
    Front Digit Health; 2022; 4():880849. PubMed ID: 35712228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practices of care among people who buy, use, and sell drugs in community settings.
    Kolla G; Strike C
    Harm Reduct J; 2020 May; 17(1):27. PubMed ID: 32381011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of COVID-19 on Drug Use and Harm Reduction Programming in the Middle East and North Africa (MENA) Region: a Regional Consultation of Stakeholders and People Who Use Drugs.
    Van Hout MC; Haddad P; Aaraj E
    Int J Ment Health Addict; 2022; 20(4):2072-2085. PubMed ID: 34276260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "We do it ourselves": strengths and opportunities for improving the practice of harm reduction.
    Claborn K; Samora J; McCormick K; Whittfield Q; Courtois F; Lozada K; Sledge D; Burwell A; Chavez S; Bailey J; Bailey C; Pederson CD; Zagorski C; Hill L; Conway FN; Steiker LH; Cance J; Potter J
    Harm Reduct J; 2023 Jun; 20(1):70. PubMed ID: 37296459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S.
    Frost MC; Sweek EW; Austin EJ; Corcorran MA; Juarez AM; Frank ND; Prohaska SM; LaKosky PA; Asher AK; Broz D; Jarlais DCD; Williams EC; Glick SN
    AIDS Behav; 2022 Jan; 26(1):57-68. PubMed ID: 34110506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harm Reduction Services in Ottawa: The Culture of Drug Use.
    Haines M; O'Byrne P
    Res Theory Nurs Pract; 2020 May; 34(2):188-202. PubMed ID: 32457123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-level influences on increased overdose risk behaviors during the COVID-19 pandemic among people who use drugs in Rhode Island: a qualitative investigation.
    Frueh L; Collins AB; Newman R; Barnett NP; Rich JD; Clark MA; Marshall BDL; Macmadu A
    Harm Reduct J; 2023 Feb; 20(1):14. PubMed ID: 36739417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substance use policy and practice in the COVID-19 pandemic: Learning from early pandemic responses through internationally comparative field data.
    Aronowitz SV; Carroll JJ; Hansen H; Jauffret-Roustide M; Parker CM; Suhail-Sindhu S; Albizu-Garcia C; Alegria M; Arrendondo J; Baldacchino A; Bluthenthal R; Bourgois P; Burraway J; Chen JS; Ekhtiari H; Elkhoy H; Farhoudian A; Friedman J; Jordan A; Kato L; Knight K; Martinez C; McNeil R; Murray H; Namirembe S; Radfar R; Roe L; Sarang A; Scherz C; Tay Wee Teck J; Textor L; Thi Hai Oanh K
    Glob Public Health; 2022 Dec; 17(12):3654-3669. PubMed ID: 36692903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.